Read by QxMD icon Read

Stage IV lung cancer

Lihong Zhang, Hongbin Wang, Xuejun Dong
OBJECTIVE: To investigate the diagnostic value of α-enolase (ENO1) and serum ENO1 autoantibody levels in lung cancer. METHODS: Immunohistochemistry staining and ELISA were performed to detect ENO1 expression in lung tissue and serum ENO1 autoantibody levels, respectively. RESULTS: The expression of ENO1 was higher in lung cancer tissues than in benign lung disease tissues (p < 0.001). The proportion of lung cancer samples expressing ENO1 was not significantly different among the various pathological classification groups...
January 2018: Jornal Brasileiro de Pneumologia: Publicaça̋o Oficial da Sociedade Brasileira de Pneumologia e Tisilogia
Matthew P Smeltzer, Fedoria E Rugless, Bianca M Jackson, Courtney L Berryman, Nicholas R Faris, Meredith A Ray, Meghan Meadows, Anita A Patel, Kristina S Roark, Satish K Kedia, Margaret M DeBon, Fayre J Crossley, Georgia Oliver, Laura M McHugh, Willeen Hastings, Orion Osborne, Jackie Osborne, Toni Ill, Mark Ill, Wynett Jones, Hyo K Lee, Raymond S Signore, Roy C Fox, Jingshan Li, Edward T Robbins, Kenneth D Ward, Lisa M Klesges, Raymond U Osarogiagbon
Background: Responsible for 25% of all US cancer deaths, lung cancer presents complex care-delivery challenges. Adoption of the highly recommended multidisciplinary care model suffers from a dearth of good quality evidence. Leading up to a prospective comparative-effectiveness study of multidisciplinary vs. serial care, we studied the implementation of a rigorously benchmarked multidisciplinary lung cancer clinic. Methods: We used a mixed-methods approach to conduct a patient-centered, combined implementation and effectiveness study of a multidisciplinary model of lung cancer care...
February 2018: Translational Lung Cancer Research
Cristina Aguado, Maria-de-Los-Llanos Gil, Zaira Yeste, Ana Giménez-Capitán, Cristina Teixidó, Niki Karachaliou, Santiago Viteri, Rafael Rosell, Miguel A Molina-Vila
Fusion of the anaplastic lymphoma receptor tyrosine kinase gene ( ALK ) with the echinoderm microtubule-associated protein 4 gene ( EML4 ) is the second most common actionable alteration in non-small-cell lung cancer, with a frequency of 5%. Here, we present a case of an EML4-ALK-positive patient with an atypical in-frame insertion from the LTBP1 gene in the canonical junction of variant 1 . The patient was a 39-year-old never-smoker female diagnosed with Stage IV lung adenocarcinoma. A core biopsy was negative for EGFR and KRAS mutations but positive for ALK immunohistochemistry and fluorescence in situ hybridization...
2018: OncoTargets and Therapy
John Michael Varlotto, Richard Voland, Kerrie McKie, John C Flickinger, Malcolm M DeCamp, Debra Maddox, Paul Rava, Thomas J Fitzgerald, Geoffrey Graeber, Negar Rassaei, Paulo Oliveira, Suhail Ali, Chandra Belani, Jonathan Glanzman, Heather A Wakelee, Manali Patel, Jennifer Baima, Jianying Zhang, William Walsh
To investigate the interrelation between economic, marital, and known histopathologic/therapeutic prognostic factors in presentation and survival of patients with lung cancer in nine different ethnic groups. A retrospective review of the SEER database was conducted through the years 2007-2012. Population differences were assessed via chi-square testing. Multivariable analyses (MVA) were used to detect overall survival (OS) differences in the total population (TP, N = 153,027) and for those patients presenting with Stage IV (N = 70,968)...
March 13, 2018: Cancer Medicine
Saiama N Waqar, Pamela P Samson, Cliff G Robinson, Jeffrey Bradley, Siddhartha Devarakonda, Lingling Du, Ramaswamy Govindan, Feng Gao, Varun Puri, Daniel Morgensztern
BACKGROUND: Data on the prevalence of brain metastases at presentation in patients with non-small-cell lung cancer (NSCLC) are limited. We queried the National Cancer Data Base to determine prevalence, clinical risk factors, and outcomes of patients with NSCLC presenting with brain metastases. PATIENTS AND METHODS: Patients with NSCLC diagnosed between 2010 and 2012 were identified using the National Cancer Data Base. The risk of brain metastases for individual variables was summarized by odds ratios and calculated using logistic regression analysis...
March 8, 2018: Clinical Lung Cancer
Stephanie E Bonn, Matt J Barnett, Mark Thornquist, Gary Goodman, Marian L Neuhouser
The aim of this study was to investigate the association between BMI (kg/m) and prostate cancer risk. BMI is a modifiable lifestyle factor and may provide a unique opportunity for primary prevention of prostate cancer if a causal association exists. Data from 11 886 men from the Carotene and Retinol Efficacy Trial (CARET, 1985-1996 with active follow-up through 2005) comprising current and former heavy smokers were analyzed. CARET was a multicenter randomized, double-blind placebo-controlled chemoprevention trial testing daily supplementation of 30 mg β-carotene+25 000 IU retinyl palmitate for primary prevention of lung cancer...
March 7, 2018: European Journal of Cancer Prevention
You-Cai Zhu, Yue-Fen Zhou, Wen-Xian Wang, Chun-Wei Xu, Wu Zhuang, Kai-Qi Du, Gang Chen
ROS1 rearrangement is a validated therapeutic driver gene in non-small cell lung cancer (NSCLC) and represents a small subset (1-2%) of NSCLC. A total of 17 different fusion partner genes of ROS1 in NSCLC have been reported. The multi-targeted MET/ALK/ROS1 tyrosine kinase inhibitor (TKI) crizotinib has demonstrated remarkable efficacy in ROS1-rearranged NSCLC. Consequently, ROS1 detection assays include fluorescence in situ hybridization, immunohistochemistry, and real-time PCR. Next-generation sequencing (NGS) assay covers a range of fusion genes and approaches to discover novel receptor-kinase rearrangements in lung cancer...
March 8, 2018: Thoracic Cancer
Takuro Kometani, Kenji Sugio, Atsushi Osoegawa, Takashi Seto, Yukito Ichinose
BACKGROUND: The EML4-ALK fusion gene has recently been identified as a driver mutation in a subset of non-small cell lung cancers. In subsequent studies, EML4-ALK has been detected in a low percentage of patients, and was associated with a lack of EGFR or KRAS mutations, younger age, and adenocarcinoma with acinar histology. Cases with the EML4-ALK fusion gene were examined to clarify the clinicopathological characteristics of young adenocarcinoma patients. METHODS: Between December 1998 and May 2009, 85 patients aged ≤ 50 with lung adenocarcinoma were treated at our hospital...
March 8, 2018: Thoracic Cancer
Satoshi Fukai, Naoyuki Okabe, Hayato Mine, Hironori Takagi, Hiroyuki Suzuki
BACKGROUND: Garcin syndrome, which consists of unilateral palsies of almost all cranial nerves without either sensory or motor long-tract disturbances or intracranial hypertension, can be caused by malignant tumors at the skull base. The case of a patient with lung cancer that metastasized to the sphenoid bone and resulted in Garcin syndrome is presented. CASE PRESENTATION: A 76-year-old woman was diagnosed as having non-small cell lung cancer with pericardial and diaphragmatic infiltration, cT4N1M0, stage 3A...
March 6, 2018: World Journal of Surgical Oncology
Boris Sepesi, David B Nelson, Kyle G Mitchell, Don L Gibbons, John V Heymach, Ara A Vaporciyan, Stephen G Swisher, Jason Roszik
BACKGROUND: Immune checkpoint inhibitors targeting the PD-L1 pathway have shown benefit for the treatment of metastatic non-small cell lung cancer (NSCLC). However, the prognostic value of PD-L1 independent of immunotherapy is still unclear, with conflicting results reported between PD-L1 expression and patient survival. Our aim was to correlate PD-L1 mRNA level with clinical and pathologic factors and to investigative the prognostic value of PD-L1 mRNA in all stages of NSCLC. METHODS: Gene expression and clinical data were obtained from public TCGA repositories from the National Cancer Institute...
March 3, 2018: Annals of Thoracic Surgery
Minggui Pan, Maqdooda Merchant
Synovial sarcoma is a high-grade soft tissue sarcoma that inflicts mostly children and young adults with high mortality rate; however, the risk factors that impact the outcomes remain incompletely understood. We have identified the synovial sarcoma cases from the Kaiser Permanente Northern California cancer registry between 1981 and 2014. Kaplan-Meier plots were used to display disease-free survival (DFS) and overall survival (OS); log-rank tests and Cox proportional hazard models were used to determine the impact of clinical factors on DFS, OS, and disease-specific survival...
March 6, 2018: Medical Sciences: Open Access Journal
H Xia, X-L Qu, L-Y Liu, D-H Qian, H-Y Jing
OBJECTIVE: Lung cancer is one of the most common malignancies worldwide, the morbidity and mortality of which have been on rising in recent years. Moreover, lncRNAs have been implicated in the development of various cancers, as well as cancer treatment and prognosis. In this study, long non-coding RNA (lncRNA) MEG3, an identified tumor suppressor, was explored for its role in the chemotherapy of lung cancer. MATERIALS AND METHODS: All cases were divided into (I+II) group and (III+IV) group according to different stages of tumor node metastasis (TNM), and were divided into sensitive group and insensitive group according to chemotherapy sensitivity...
February 2018: European Review for Medical and Pharmacological Sciences
Raymond Tsz-Tong Chan
Non-small cell lung cancers (NSCLC) harboring the uncommon epidermal growth factor receptor (EGFR) exon 20 insertion mutations are generally thought to be unresponsive to EGFR-tyrosine kinase inhibitor (TKI) therapy. Presented here is a case of stage IV NSCLC harboring an uncommon EGFR exon 20 insertion mutation that was maintained at minimal progressive disease for 54 months, with 36 months on the second-generation TKI afatinib. Contrary to the existing literature, the patient in this case demonstrated a long, durable response to the EGFR-TKI, which was exhibited by a long survival endpoint...
March 2018: Asia-Pacific Journal of Clinical Oncology
Hikmat Abdel-Razeq, Asem Mansour, Hazem Abdulelah, Anas Al-Shwayat, Mohammad Makoseh, Mohammad Ibrahim, Mahmoud Abunasser, Dalia Rimawi, Abeer Al-Rabaiah, Rozan Alfar, Alaa' Abufara, Alaa Ibrahim, Anas Bawaliz, Yousef Ismael
Background: The risk of thromboembolic events is higher among cancer patients, especially in patients undergoing chemotherapy. Cisplatin-based regimens claim to be associated with a very high thromboembolic rate. In this study, we report on our own experience with thrombosis among patients on active cisplatin-based chemotherapy. Methods: Medical records and hospital databases were searched for all the patients treated with any cisplatin-based regimen for any kind of cancer...
2018: Thrombosis Journal
Cheol-Kyu Park, In-Jae Oh, Yoo-Duk Choi, Tae-Won Jang, Jeong-Eun Lee, Jeong-Seon Ryu, Shin-Yup Lee, Young-Chul Kim
OBJECTIVES: We aimed to evaluate the prevalence and predictive role of c-MET expression and EGFR mutation in the efficacy of erlotinib in non-small-cell lung cancer (NSCLC). METHODS: We prospectively recruited 196 patients with stage IV or recurrent NSCLC treated with erlotinib after failure of first-line chemotherapy. Immunohistochemistry was used to evaluate c-MET overexpression, silver in situ hybridization (SISH) to assess gene copy number, and real-time polymerase chain reaction to detect EGFR mutations, respectively, in tumor tissue...
March 2, 2018: Oncology
Xuejia Kang, Zening Zheng, Zehua Liu, Huiyuan Wang, Yuge Zhao, Wenyuan Zhang, Mingjie Shi, Yang He, Yang Cao, Qin Xu, Chengyuan Peng, Yongzhuo Huang
Effective treatment of metastatic (stage IV) breast cancers remains a formidable challenge. To address this issue, a cell-penetrating peptide-assisted liposomal system was developed for codelivery of doxorubicin and andrographolide. This nanomedicine-based combination therapy showed the ability to inhibit the in vitro migration and invasion of 4T1 cells through the wound healing and transwell invasion assays. Furthermore, this delivery system exhibited the enhanced accumulation in the tumor tissues and deep intratumoral penetration...
March 2, 2018: Molecular Pharmaceutics
Huiyan Deng, Junying Liu, Xiaojin Duan, Yueping Liu
To detect the relationship of the epidermal growth factor receptor (EGFR) mutation status and the clinicopathologic features. Six hundred thirty-three patients with pathologically confirmed lung adenocarcinoma who underwent lung cancer resection surgery at the Fourth Hospital of Hebei Medical University between April 2012 and April 2015 were selected for the study. The 32 types of mutations in exons 18-21 of the EGFR gene were detected. The total EGFR mutation rate among patients with lung adenocarcinoma was 56...
September 21, 2017: Pathology, Research and Practice
Wenjia Yang, Fangfei Qian, Jiajun Teng, Huimin Wang, Christian Manegold, Lothar R Pilz, Weiland Voigt, Yanwei Zhang, Jianding Ye, Qunhui Chen, Baohui Han
OBJECTIVES: To investigate whether low-dose computed tomography (LDCT) screening is capable of enhancing the detection rate of early-stage lung cancer in high-risk population of China with both smoking and non-smoking related factors. METHODS: From 2013-2014, eligible participants with high-risk factors of lung cancer were randomly assigned to a screening group or a control group with questionnaire inquiries. Any non-calcified nodules or masses with longest diameters of ≥4 mm identified on LDCT images were considered as positive...
March 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
Romain Corre, Radj Gervais, Florian Guisier, Louis Tassy, Florent Vinas, Régine Lamy, Gislaine Fraboulet, Laurent Greillier, Helene Doubre, Renaud Descourt, Christos Chouaid, Jean-Bernard Auliac
Objective: To assess efficacy and tolerance of EGFR tyrosine-kinase inhibitors (TKIs) for advanced EGFR-mutated non-small cell lung cancer (NSCLC) in octogenarians. Patients and methods: Patients aged 80 years or older with EGFR-mutated NSCLC treated by EGFR TKI between January 2011 and March 2015 whatever the line of treatment were retrospectively selected. Results: 20 centers retrospectively included 114 patients (women, 77.2%; Caucasians, 98...
February 2, 2018: Oncotarget
Dae Ho Lee, Hiroshi Isobe, Hubert Wirtz, Sabina Bandeira Aleixo, Phillip Parente, Filippo de Marinis, Min Huang, Ashwini Arunachalam, Smita Kothari, Xiting Cao, Nello Donnini, Ann-Marie Woodgate, Javier de Castro
BACKGROUND: Data are scarce regarding real-world health care resource use (HCRU) for non-small cell lung cancer (NSCLC). An understanding of current clinical practices and HCRU is needed to provide a benchmark for rapidly evolving NSCLC management recommendations and therapeutic options. The objective of this study was to describe real-world HCRU for patients with advanced NSCLC. METHODS: This multinational, retrospective chart review study was conducted at academic and community oncology sites in Italy, Spain, Germany, Australia, Japan, South Korea, Taiwan, and Brazil...
March 1, 2018: BMC Health Services Research
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"